PhaseRx’s (NASDAQ:PZRX) lock-up period will expire on Monday, November 14th. PhaseRx had issued 3,700,000 shares in its initial public offering on May 18th. The total size of the offering was $18,500,000 based on an initial share price of $5.00. After the end of PhaseRx’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Shares of PhaseRx (NASDAQ:PZRX) opened at 1.078 on Friday. PhaseRx has a 52 week low of $0.96 and a 52 week high of $5.77. The stock has a 50 day moving average price of $1.87 and a 200-day moving average price of $3.31. The firm’s market capitalization is $15.85 billion.

PhaseRx (NASDAQ:PZRX) last announced its earnings results on Monday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. On average, analysts anticipate that PhaseRx will post ($0.92) EPS for the current year.

About PhaseRx

PhaseRx, Inc is a preclinical biopharmaceutical company. The Company develops a portfolio of products for the treatment of inherited enzyme deficiencies in the liver, using intracellular enzyme replacement therapy, i-ERT. Its i-estrogen replacement therapy (ERT) approach is enabled by its Hybrid messenger ribonucleic acid (RNA), or messenger ribonucleic acid (mRNA), Technology platform, which allows synthesis of the missing enzyme inside the cell.

5 Day Chart for NASDAQ:PZRX

Receive News & Stock Ratings for PhaseRx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc and related stocks with our FREE daily email newsletter.